Drug
JS111 clinical trials
- studies test it
- 3
- open now
- 1
- in phase 3
- 0
- first study started
- 2021
Keep track of what changes. Save the JS111 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses JS111 is read from its arms, and is right about nine times in ten.
Testing it · 3
- JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLCNot yet recruitingNot applicableHuan ZhouNCT07714304Written as JS111 capsules (AP-L1898)
- AP-L1898 Capsule in Patients With Non-small Cell Lung CancerTerminatedPhase 1/2Suzhou Junjing BioSciences Co., Ltd.NCT04993391Written as JS111(AP-L1898 Capsules)
- JS111 in Patients With Advanced NSCLC Harboring EGFR MutationsActive, not recruitingPhase 1/2Suzhou Junjing BioSciences Co., Ltd.NCT06940401Written as JS111 capsules (AP-L1898)